RFK and Peptides: How Policy Changes Could Affect Peptide Access

Key Takeaways

• The February 27, 2026 announcement: HHS Secretary Robert F. Kennedy Jr. referenced approximately fourteen peptides on the FDA's Category 2 restricted-from-compounding list, indicating HHS leadership supported restoring compounding access. This was a statement of regulatory intent, not a rule.
• The April 15, 2026 FDA update: FDA published a formal update removing twelve peptide bulk drug substances from Category 2 of the interim 503A bulks list (nominations withdrawn), and separately removed injectable GHK-Cu from Category 1. The twelve removed-from-Category-2 substances were NOT added to Category 1 and are NOT on the 503A bulk drug substances list; they occupy a pending-review regulatory status. Pharmacy Compounding Advisory Committee review is scheduled for July 23–24, 2026 and subsequent dates. Until PCAC review concludes and FDA takes final action, compounding of these substances under 503A carries meaningful regulatory risk.
• What has not changed: FDA-approved peptides (semaglutide, tirzepatide, tesamorelin, etc.) were not affected by any of these actions. Substances not yet reclassified remain restricted from compounding. No compounded peptide has received FDA approval through any of these actions.
• The underlying policy debate: The access-versus-safety trade-off in peptide regulation is not new. Professional medical societies, regulators, and researchers have debated it for years. The February 27, 2026 HHS statements brought the debate to broader public attention; the underlying regulatory and clinical questions remain under review.
• Governing law: Federal Food, Drug, and Cosmetic Act (FDCA), Sections 503A and 503B; Drug Quality and Security Act (DQSA) of 2013.
• Primary regulator: FDA Center for Drug Evaluation and Research (CDER) for drug and compounding law; state pharmacy boards for compounding facility oversight.

The Regulatory Framework Governing Peptides

Before examining what the Kennedy-era policy changes mean, it is necessary to understand the framework those changes are operating within. Peptides in the United States occupy four regulatory categories: FDA-approved drugs dispensed by prescription, bulk drug substances compoundable under Section 503A of the FDCA, dietary supplements governed by DSHEA, and unregulated products sold outside any legal framework for human use.

The September 2023 FDA action that RFK Jr.'s announcement addressed was an update to the third tier — the 503A compounding list. It did not affect FDA-approved peptides or dietary supplements. The Pharmacy Compounding Advisory Committee (PCAC) is the formal mechanism through which FDA evaluates bulk drug substance nominations for compounding eligibility; its review process is the formal pathway through which Category 2 designations can be revised.

What makes a substance Category 2

Category 2 designates substances that FDA has placed on a do-not-compound list under Section 503A — typically after finding insufficient published clinical safety data, immunogenicity risk, manufacturing and impurity concerns, or the existence of an FDA-approved alternative that makes compounding unnecessary. Cabaleiro, writing in a 2021 analysis in the International Journal of Pharmaceutical Compounding, described the step-by-step legal framework FDA uses to determine compounding eligibility for a substance. The Category 2 designation does not make a molecule federally illegal — it restricts its compounding and commercial distribution. Marketing, distribution, or importation of an unapproved peptide for human use remains subject to FDA's intended use doctrine under 21 CFR § 201.128 regardless of Category 2 status. Sellers and purchasers cannot rely on Category 2 removal as authorization for any human-use distribution channel outside of a licensed prescriber, a valid prescription, and a compounding pharmacy operating with a qualifying bulk drug substance. That distinction affects how any policy change should be understood: removal from Category 2, or subsequent reclassification to Category 1, restores compounding eligibility only when the substance meets the criteria; it does not confer FDA approval.

The Drug Quality and Security Act as the baseline

The current 503A framework exists because of the DQSA of 2013. Gabay, in a 2014 review in Hospital Pharmacy, explained how the DQSA restructured compounding law following the 2012 New England Compounding Center meningitis outbreak, which killed 64 people and injured hundreds after contaminated injectable methylprednisolone was distributed from an unregulated compounding facility. That outbreak is the historical anchor for the entire post-2013 regulatory framework. Any policy discussion about loosening compounding oversight operates in that context — not as an abstract regulatory question, but as a response to documented harm from inadequate compounding standards.

The February 27, 2026 HHS Announcement: Scope and Regulatory Weight

Public statements by HHS Secretary Kennedy in early 2026 expressed support for restoring compounding access to peptides that had been on the Category 2 list since September 2023. The statements were made in public forums and in communications reported across health media. They were interpreted by many in the peptide wellness space as a reversal of the FDA peptide restrictions.

The statements were not a regulatory action. HHS secretaries can direct policy priorities and instruct FDA leadership, but they cannot unilaterally revise the 503A bulk drug substances list. That list is updated by FDA after a process that typically includes Pharmacy Compounding Advisory Committee (PCAC) review and public comment. PCAC is advisory; the final determination on whether to add a substance to the 503A list rests with FDA. The February 27, 2026 announcement set that process in motion for the specified substances; the April 15, 2026 FDA publication was the first formal output of that process.

The distinction between announcement and rule

This distinction matters for patients, providers, and pharmacies. Between February 27 and April 15, 2026, the Category 2 restrictions remained operative. A compounding pharmacy that began compounding a Category 2 substance following the February announcement — before the April 15 publication — would have been doing so outside the legal framework regardless of the political signal. The April 15 publication, with its seven-day effective date, is the date from which compounding of the twelve reclassified substances became legally permitted. Zettler and colleagues, in a 2026 analysis published in the Journal of Health Politics, Policy and Law, examined scope and magnitude of recent FDA regulatory activity, providing peer-reviewed context for the regulatory environment in which these peptide-policy discussions are occurring.

503A Compounding and the Category 2 Timeline

Understanding the September 2023 restriction and the April 2026 update requires understanding the compounding framework in which both occurred.

September 2023: nineteen peptides restricted

On September 29, 2023, FDA updated the interim 503A bulks list to move a group of peptide bulk drug substances to Category 2 (the restricted-from-compounding category), citing insufficient data to support safe compounding. The designated substances included several commonly referenced compounds: ipamorelin, CJC-1295, BPC-157, sermorelin, TB-500, and bulk bremelanotide for compounding (distinct from the FDA-approved drug Vyleesi, which is unaffected), among others. The restrictions were based on FDA's determination that these substances presented significant safety concerns or had insufficient evidence to support safe compounding. The action affected a large number of patients who had been receiving these compounds through licensed compounding pharmacies and generated demand for information about alternatives. Readers should consult the FDA 503A bulk drug substances resource at FDA.gov for the authoritative list of substances affected by the September 2023 action.

February 27, 2026: announcement of intent

The Kennedy announcement on February 27, 2026 represented HHS leadership's formal position that the September 2023 restrictions had been applied too broadly. The Obesity Medicine Association, in its 2024 statement published in Obesity Pillars by Bays and colleagues, addressed the compounded GLP-1 market that had emerged during FDA-declared shortages of semaglutide and tirzepatide. OMA generally urged use of FDA-approved products when available and flagged safety and quality concerns with compounded copies, while acknowledging patient access challenges. OMA did not call for loosening compounding restrictions on unapproved peptides generally.

April 15, 2026: formal update removing twelve substances from Category 2

The April 15, 2026 FDA publication removed twelve peptide bulk drug substances — including BPC-157, LL-37, DiHexa, DSIP, Epitalon, KPV, PEG-MGF, Melanotan II, MOTS-c, Semax, and TB-500 — from Category 2 of the interim 503A bulks list, citing withdrawn nominations. In a separate action on the same date, FDA removed injectable GHK-Cu from Category 1 due to a withdrawn nomination — a restriction, not an expansion. The seven-day effective date made removal from Category 2 effective on approximately April 22, 2026. Critically, these substances were NOT added to Category 1 and were NOT placed on the 503A bulk drug substances list. They remain in a pending-review regulatory status. The Pharmacy Compounding Advisory Committee is scheduled to evaluate most of these substances on July 23–24, 2026 (BPC-157, KPV, MOTS-c, TB-500, and others on July 23; Emideltide, Epitalon, Semax on July 24), with remaining evaluations continuing through February 2027. Until PCAC review concludes and FDA takes final action, compounding of these substances under 503A carries meaningful regulatory risk. Prescribers and pharmacies should consult the current FDA 503A bulk drug substances resource and a healthcare regulatory attorney before relying on this change to support compounding. The formal FDA 503A compounding resource, available at FDA.gov — Human Drug Compounding, is the authoritative source for current Category designations.

The Access-versus-Safety Trade-Off

The policy debate that RFK Jr.'s statements have brought to wider public attention is not new. The tension between patient access to compounds with promising preclinical or early human evidence and the safety protections that require more rigorous evaluation before broad access is permitted has been a central tension in compounding regulation for over a decade.

The case for expanded access

The access argument rests on two pillars. First, some restricted peptides have genuine clinical research backing — early human trials, published mechanisms, and prescriber-documented clinical outcomes — that the Category 2 designation may not fully reflect. A 2025 analysis by Wimalawansa in the journal Foods proposed restructuring FDA oversight to create clearer pathways for compounds that sit between conventional drugs and nutritional products. Second, the cost of FDA-approved alternatives for some indications is high. A 2024 net price analysis by Hernandez and Sullivan published in Obesity found that even after manufacturer discounts (41% for obesity indications; 54–59% for type 2 diabetes), FDA-approved GLP-1 peptides remained priced at $717–$761 per month for obesity and $312–$469 per month for type 2 diabetes — costs that drive patients toward compounded or gray-market alternatives when coverage is unavailable. A 2025 cross-sectional analysis published in JAMA Network Open documented the coverage and prior authorization barriers facing even FDA-approved semaglutide and tirzepatide across Medicare Part D plans.

The case for maintaining quality standards

The safety argument is empirical. A 2021 systematic review by Watson and colleagues in the Journal of Medical Toxicology identified 63 documented compounding errors, with contamination errors harming the most patients (1,119 patients across 27 contamination events). The 2012 meningitis outbreak — in which inadequate oversight of a compounding facility resulted in 64 deaths and hundreds of injuries — was documented by Teshome and colleagues in a 2014 analysis in the Journal of the American Pharmacists Association as the direct consequence of regulatory gaps in compounding oversight. A 2018 analysis by Janvier and colleagues in Talanta documented falsified peptide products with purity ranging from 5 to 75 percent and heavy metal contamination in products circulating outside regulated channels. These data represent the documented endpoint of unregulated peptide access — not a theoretical concern.

A 2026 analysis by Belcourt and colleagues in the Annals of Pharmacotherapy characterized 33 unique compounded semaglutide and tirzepatide products, finding that 48% contained combinations of added cyanocobalamin, glycine, niacinamide, docusate, or ondansetron — ingredients for which there is limited justification and no standardized safety or efficacy data in subcutaneous formulations. Zane and colleagues, in a 2021 review in the International Journal of Toxicology, noted the absence of peptide-specific FDA guidance and the regulatory challenges this creates for manufacturers and regulators alike. And a 2026 narrative review by Mendias and colleagues in Sports Medicine noted that unapproved peptide therapies marketed direct to consumers show promising preclinical data but that rigorous human safety data are scarce.

What the compounding error data show

A 2022 FDA warning letter analysis by Dmour and colleagues in the Journal of Pharmaceutical Innovation examined 141 FDA warning letters to compounding pharmacies between 2017 and 2022, documenting widespread violations including contamination, sterility failures, and label inaccuracies. These violations occurred within the existing regulatory framework — not in the gray market. The policy implication is that enforcement capacity matters: weakening FDA oversight authority, as some reform proposals suggest, may increase the frequency of these violations rather than improve access.

Current Legal Status as of April 2026

As of April 2026, the regulatory landscape for peptides reflects the outcomes of both the September 2023 restrictions and the April 2026 update. The following reflects the state of law as of the date of this article and is subject to change as PCAC review continues.

FDA-approved peptides (unchanged)

Semaglutide, tirzepatide, tesamorelin, octreotide, leuprolide, and the dozens of other FDA-approved peptide drugs were not affected by the September 2023 restrictions or the April 2026 update. As documented by Al Musaimi in a 2024 review in Biomolecules, the pipeline of FDA-approved peptide drugs is large and growing across cardiovascular, metabolic, oncological, and endocrine indications. These compounds are legal with a prescription and have not been subject to any compounding restriction debate.

503A Category 1 peptides (compoundable with prescription, as of April 2026)

The existing Category 1 list remains compoundable under 503A. Access requires a valid prescription from a licensed prescriber with a valid prescriber-patient relationship, subject to state-specific medical board and pharmacy board requirements. Some states require an initial in-person evaluation before a telehealth-originated prescription for compounded injectables; verify current requirements for your jurisdiction with counsel. Hoffman's 2020 analysis in the American Journal of Law and Medicine examined the legal landscape for telemedicine prescribing. Note: the twelve substances removed from Category 2 on April 15, 2026 were NOT added to the Category 1 list; they are in a pending-PCAC-review status and do not have a clear 503A compounding pathway at this time.

Category 2 peptides (still restricted as of April 2026)

The substances not addressed in the April 15 update remain on the Category 2 restricted list. PCAC review is ongoing; no timeline for further determinations has been publicly announced. Category 2 means restricted from compounding under 503A. Marketing, distribution, or importation of an unapproved peptide for human use remains subject to FDA's intended use doctrine under 21 CFR § 201.128 regardless of Category 2 status. Consult the FDA's current 503A bulk drug substances resource for the authoritative up-to-date list.

Unregulated gray-market products

Peptides sold through online vendors without prescription requirements remain outside the legal framework for human therapeutic use, regardless of any recent reclassification actions. The reclassification of a substance to Category 1 permits compounding by licensed 503A pharmacies — it does not license gray-market vendors to sell that compound for human use. A 2016 analysis by Pinkerton and colleagues in Menopause reviewed the regulatory conditions that separate lawful compounding from unlawful distribution; those conditions require a licensed prescriber, a valid prescription, and a licensed pharmacy.

State-by-State Variation

Federal law governs the 503A compounding framework. State pharmacy boards add requirements on top of federal minimums, governing pharmacy licensure, telehealth prescribing rules, and in some cases specific restrictions on compounded substances. The legal landscape for an individual patient depends on both federal and state law. Hoffman's 2020 review examined how state telehealth prescribing requirements vary substantially, affecting which prescriber-patient relationships can lawfully support a compounded peptide prescription.

• Telehealth prescribing rules: Some states require an in-person evaluation before compounded drug prescriptions can be issued via telehealth. Others permit audio-video-only telehealth prescribing for compounded medications. Verify your state's requirements with your provider.
• Pharmacy board standards: State boards may impose USP 797 and USP 795 sterility and beyond-use dating standards beyond the federal 503A minimums. PCAB-accredited pharmacies typically meet or exceed these requirements.
• Controlled substance scheduling: Peptides are not federally scheduled controlled substances, but state-level scheduling may apply to specific compounds or ancillary preparations.

For questions about specific state compliance, consult a licensed healthcare regulatory attorney in your state.

What This Means for Consumers

The practical implications of the 2026 policy changes depend on which compounds you are currently using or considering.

The legal pathway to compounded peptide access

As of April 2026, the legal pathway to compounded injectable peptides remains unchanged in structure: a licensed healthcare provider with prescribing authority in your state, a valid prescriber-patient relationship (which may be established via telehealth in most states), a prescription for a Category 1 substance, and a 503A-licensed compounding pharmacy. The April 2026 update expanded the number of substances available through this pathway; it did not change the pathway itself.

Questions to ask your provider

• Is the compound you are prescribing on the current Category 1 list as of April 2026?
• Is the pharmacy you use 503A-licensed and PCAB-accredited?
• Has the FDA published any safety communications about this compound that affect the prescribing rationale?
• Is there an FDA-approved alternative for this indication?

What This Means for Providers

Consistent with the 503A framework as currently published, prescribers writing for compounded peptides following the April 2026 update should verify that each substance they prescribe meets § 503A(b)(1)(A) qualifying criteria before issuing a prescription. Importantly, the twelve substances removed from Category 2 on April 15, 2026 were NOT added to Category 1 or placed on the 503A bulk drug substances list; they remain in pending-PCAC-review status, and prescribing or compounding them in the interim exposes both the prescriber and the compounding pharmacy to regulatory risk. For specific compliance guidance, providers should consult with a healthcare regulatory attorney familiar with both federal FDCA requirements and their state's pharmacy law.

Pharmacy obligations

As a general matter under 503A, a pharmacy that receives a prescription for a substance on the Category 2 list — regardless of signaled intent about future reclassification — cannot lawfully compound that substance until the formal FDA publication takes effect. In the same framework, substances that have been removed from Category 2 but not placed on the 503A bulk drug substances list do not have a clear 503A compounding pathway pending PCAC review. Dmour and colleagues' 2022 analysis of FDA warning letters documented the types of violations that generate enforcement action; proceeding ahead of a formal regulatory change would fall into that category.

When to Take the Regulatory Landscape Seriously

The policy debate about peptide access is ultimately a debate about where to locate the balance between patient access and patient protection. The 2012 meningitis outbreak, documented by Teshome and colleagues, showed that inadequate compounding oversight can produce identifiable, preventable harm. The access barriers created by high drug prices and limited insurance coverage, documented across multiple peer-reviewed analyses, cause their own form of identifiable harm. Neither concern overrides the other.

What both concerns share is a reliance on objective health data. The patients most likely to benefit from peptide therapy — whether FDA-approved or compounded — are those whose providers have a clear picture of baseline biology: metabolic markers, hormonal baselines, inflammatory status. Testing IGF-1, HbA1c, and a comprehensive metabolic baseline before starting any compound provides the clinical context that makes the prescriber's evaluation substantive rather than speculative. That principle — test first, then decide — is foundational to Superpower's approach to preventive health regardless of how the policy landscape evolves.

REGULATORY INFORMATION NOTICE

This article reflects the regulatory landscape as of April 2026. Regulatory status of peptides changes frequently, including through FDA guidance documents, Federal Register publications, Pharmacy Compounding Advisory Committee recommendations, and judicial decisions. The April 15, 2026 FDA update described in this article was the most recent formal change as of the publication date; subsequent updates may have modified the Category 2 list further. Superpower makes no representation that the information above is current as of any date after its publication. Always verify current FDA guidance at FDA.gov — Human Drug Compounding.

This article does not constitute legal advice. For guidance on specific compounding compliance, prescribing requirements, or regulatory questions in your jurisdiction, consult a licensed healthcare regulatory attorney or your state pharmacy board.

Superpower Health does not provide legal advice. Superpower's care model operates through licensed healthcare providers and 503A-compliant compounding pharmacy partners. For information about Superpower's services, visit superpower.com/how-it-works.